A skewed thiopurine metabolism is a common clinical phenomenon that can be successfully managed with a combination of low-dose azathioprine and allopurinol

被引:18
作者
Appell, Malin Lindqvist [1 ]
Wagner, Agnieszka [2 ]
Hindorf, Ulf [3 ]
机构
[1] Linkoping Univ, Dept Med & Hlth Sci, Div Drug Res Clin Pharmacol, Linkoping, Sweden
[2] Blekinge Hosp, Dept Med, Karlskrona, Sweden
[3] Skane Univ Hosp, Dept Gastroenterol, S-22185 Lund, Sweden
关键词
Thiopurine methyltransferase; Thiopurines; Inflammatory bowel diseases; INFLAMMATORY-BOWEL-DISEASE; LONG-TERM; THERAPY; 6-THIOGUANINE; PHARMACOGENETICS; MERCAPTOPURINE; HEPATOTOXICITY; STRATEGY;
D O I
10.1016/j.crohns.2012.10.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background and aims: A skewed thiopurine metabolism is a phenomenon associated with both poor treatment response and toxicity. Our aim was to evaluate the frequency of this phenomenon and the relationship to thiopurine methyltransferase (TPMT) function. Methods: All thiopurine metabolite measurements in adult patients (n=4033) between January 2006 and April 2012 were assessed to evaluate the occurrence of a skewed metabolism and the relationship to TPMT genotype and activity. Results: A skewed metabolism was observed in 14% of all patients. It only developed in patients with a normal TPMT genotype, but was observed at all TPMT activity levels within the normal range (9.1-24.2 U/ml RBC). Two cases that illustrate typical clinical scenarios of a skewed metabolism and the effect of combination treatment with low-dose azathioprine and allopurinol are presented. Conclusions: A skewed metabolism is a common clinical phenomenon in patients with a normal TPMT function, which can develop at all TPMT activity levels within the normal range. We suggest that metabolite measurements should be considered in patients not responding to treatment and in those with hepatotoxicity or myelotoxicity in order to detect a skewed metabolism, since this phenomenon can be successfully managed by a combination of low-dose azathioprine and allopurinol. (C) 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:510 / 513
页数:4
相关论文
共 21 条
[1]
6-Thioguanine therapy in Crohn's disease-Observational data in Swedish patients [J].
Almer, S. H. C. ;
Hjortswang, H. ;
Hindorf, U. .
DIGESTIVE AND LIVER DISEASE, 2009, 41 (03) :194-200
[2]
Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease [J].
Ansari, A. ;
Elliott, T. ;
Baburajan, B. ;
Mayhead, P. ;
O'Donohue, J. ;
Chocair, P. ;
Sanderson, J. ;
Duley, J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (06) :734-741
[3]
Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease [J].
Ansari, A. ;
Patel, N. ;
Sanderson, J. ;
O'Donohue, J. ;
Duley, J. A. ;
Florin, T. H. J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (06) :640-647
[4]
Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease [J].
Chouchana, L. ;
Narjoz, C. ;
Beaune, P. ;
Loriot, M-A ;
Roblin, X. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (01) :15-36
[5]
Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients [J].
de Boer, N. K. H. ;
Zondervan, P. E. ;
Gilissen, L. P. L. ;
den Hartog, G. ;
Westerveld, B. D. ;
Derijks, L. J. J. ;
Bloemena, E. ;
Engels, L. G. J. B. ;
van Bodegraven, A. A. ;
Mulder, C. J. J. .
DIGESTIVE AND LIVER DISEASE, 2008, 40 (02) :108-113
[6]
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients [J].
Dubinsky, MC ;
Vasiliauskas, EA ;
Singh, H ;
Abreu, MT ;
Papadakis, KA ;
Tran, T ;
Martin, P ;
Vierling, JM ;
Geller, SA ;
Targan, SR ;
Poordad, FF .
GASTROENTEROLOGY, 2003, 125 (02) :298-303
[7]
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease [J].
Dubinsky, MC ;
Yang, HY ;
Hassard, PV ;
Seidman, EG ;
Kam, LY ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
GASTROENTEROLOGY, 2002, 122 (04) :904-915
[8]
Toxicity of 6-thioguanine:: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine -: Some evidence for dose or metabolite level dependent effects? [J].
Gilissen, L. P. L. ;
Derijks, L. J. J. ;
Driessen, A. ;
Bos, L. P. ;
Hooymans, P. M. ;
Stockbrugger, R. W. ;
Engels, L. G. J. B. .
DIGESTIVE AND LIVER DISEASE, 2007, 39 (02) :156-159
[9]
Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients [J].
Gonzalez-Lama, Y. ;
Bermejo, F. ;
Lopez-Sanroman, A. ;
Garcia-Sanchez, V. ;
Esteve, M. ;
Cabriada, J. L. ;
McNicholl, A. G. ;
Pajares, R. ;
Casellas, F. ;
Merino, O. ;
Carpio, D. ;
Vera, M. I. ;
Munoz, C. ;
Calvo, M. ;
Benito, L. M. ;
Bujanda, L. ;
Garcia-Fernandez, F. J. ;
Ricart, E. ;
Ginard, D. ;
Velasco, M. ;
Carneros, J. A. ;
Mancenido, N. ;
Calvo, M. ;
Algaba, A. ;
Froilan, C. ;
Cara, C. ;
Mate, J. ;
Abreu, L. ;
Gisbert, J. P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (05) :544-554
[10]
Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease [J].
Hindorf, U. ;
Lindqvist, M. ;
Peterson, C. ;
Soderkvist, P. ;
Strom, M. ;
Hjortswang, H. ;
Pousette, A. ;
Almer, S. .
GUT, 2006, 55 (10) :1423-1431